Feb 14, 2023 / 04:20PM GMT
David Reed Risinger - SVB Securities LLC, Research Division - Senior MD
Great. Good morning, everybody, and thank you for joining us for this next session with Gilead. On behalf of SVB Securities, I'm very pleased to host Merdad Parsey from the company to discuss the company's pipeline prospects.
And so, Merdad, it would be great for you to maybe just comment very briefly, at a high level, about the position you see Gilead in today versus, obviously, where it was even just 9 to 12 months ago.
Merdad V. Parsey - Gilead Sciences, Inc. - Chief Medical Officer
Sure. Sure. Thanks, David, and thanks for the invitation, happy to. Look, maybe I'll go back a little bit further than 9, 12 months ago. When I joined, it's been just over 3 years now, we set out on a course of really adapting our pipeline and really building Gilead into a company that was going to be -- is going to be sustainable for the long run, really building on the strength of our HIV and virology pipeline and portfolio, but really growing into oncology in particular, as well as building out our
Gilead Sciences Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers